FDA Grants Approval for Rifapentine ANDA217042 by Macleods Pharmaceuticals
The FDA has granted approval for the ANDA217042 application for Rifapentine submitted by Macleods Pharmaceuticals.
Therapeutic Area
Therapeutic area intelligence for Antitubercular with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.